Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AESI NASDAQ:CCOI NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAESIAtlas Energy Solutions$13.43-1.3%$13.52$11.76▼$26.86$1.66B1.21.41 million shs922,384 shsCCOICogent Communications$50.00-5.5%$48.74$43.65▼$86.76$2.47B0.73505,080 shs1.25 million shsREGNRegeneron Pharmaceuticals$542.52-1.4%$544.44$476.49▼$1,211.20$58.57B0.33929,805 shs1.31 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAESIAtlas Energy Solutions0.00%-6.74%-8.02%-4.89%-38.45%CCOICogent Communications0.00%+1.21%+7.00%-5.84%-24.37%REGNRegeneron Pharmaceuticals0.00%-4.44%+5.63%-3.67%-50.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAESIAtlas Energy Solutions4.004 of 5 stars3.22.02.50.02.82.52.5CCOICogent Communications4.4556 of 5 stars3.31.03.32.83.33.30.6REGNRegeneron Pharmaceuticals4.815 of 5 stars4.43.01.72.32.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAESIAtlas Energy Solutions 2.36Hold$19.1142.30% UpsideCCOICogent Communications 2.50Moderate Buy$75.7551.50% UpsideREGNRegeneron Pharmaceuticals 2.80Moderate Buy$814.5750.14% UpsideCurrent Analyst Ratings BreakdownLatest CCOI, AESI, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025AESIAtlas Energy SolutionsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.507/15/2025AESIAtlas Energy SolutionsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$16.007/11/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$560.00 ➝ $584.007/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$755.00 ➝ $754.006/30/2025REGNRegeneron PharmaceuticalsArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAESIAtlas Energy Solutions$1.06B1.57$1.70 per share7.88$9.40 per share1.43CCOICogent Communications$1.04B2.38$0.97 per share51.51$4.55 per share10.99REGNRegeneron Pharmaceuticals$14.20B4.12$45.71 per share11.87$268.50 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAESIAtlas Energy Solutions$59.94M$0.3143.328.95N/A2.96%4.99%2.70%8/4/2025 (Estimated)CCOICogent Communications-$204.07M-$4.01N/AN/AN/A-18.76%-70.29%-6.05%8/7/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2813.8114.272.0131.94%15.27%11.93%8/1/2025 (Estimated)Latest CCOI, AESI, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CCOICogent Communications-$0.77N/AN/AN/A$247.79 millionN/A8/4/2025Q2 2025AESIAtlas Energy Solutions$0.15N/AN/AN/A$293.56 millionN/A8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.53N/AN/AN/A$3.30 billionN/A5/8/2025Q1 2025CCOICogent Communications-$1.05-$1.09-$0.04-$1.09$250.81 million$247.05 million5/5/2025Q1 2025AESIAtlas Energy Solutions$0.18$0.08-$0.10$0.01$291.13 million$297.59 million4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAESIAtlas Energy Solutions$1.007.45%N/A322.58%2 YearsCCOICogent Communications$4.048.08%N/AN/A 14 YearsREGNRegeneron Pharmaceuticals$3.520.65%N/A8.96%N/ALatest CCOI, AESI, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/7/2025CCOICogent Communicationsquarterly$1.018.11%5/22/20255/22/20256/6/20255/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/20255/5/2025AESIAtlas Energy Solutionsquarterly$0.257.12%5/15/20255/15/20255/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAESIAtlas Energy Solutions0.381.621.40CCOICogent Communications13.891.491.49REGNRegeneron Pharmaceuticals0.094.934.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAESIAtlas Energy Solutions34.59%CCOICogent Communications92.45%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipAESIAtlas Energy Solutions15.98%CCOICogent Communications11.40%REGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAESIAtlas Energy Solutions1,143123.62 million103.87 millionOptionableCCOICogent Communications1,91649.34 million43.71 millionOptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableCCOI, AESI, and REGN HeadlinesRecent News About These CompaniesBalentine LLC Invests $680,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 9:18 AM | marketbeat.comVictory Capital Management Inc. Sells 42,722 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 6:15 AM | marketbeat.comEdgestream Partners L.P. Sells 6,573 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 5:18 AM | marketbeat.comCwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 4:45 AM | marketbeat.comRegeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer?July 18 at 12:57 PM | tipranks.comRegeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?July 18 at 10:56 AM | zacks.comEvergreen Wealth Management LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 18 at 10:26 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bailard Inc.July 18 at 8:41 AM | marketbeat.comWealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 18 at 5:58 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth PartnersJuly 17 at 8:10 AM | marketbeat.comCullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 17 at 7:13 AM | marketbeat.comUBS Raises Regeneron (REGN) Price Target, Maintains Neutral RatingJuly 16, 2025 | msn.comRegeneron Advances Melanoma Treatment with New Phase 2 TrialJuly 16, 2025 | tipranks.comRegeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 TrialJuly 16, 2025 | tipranks.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Grandfield & Dodd LLCJuly 16, 2025 | marketbeat.comApollon Wealth Management LLC Has $2.22 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 16, 2025 | marketbeat.com1 Healthcare Stock on Our Buy List and 2 to Brush OffJuly 15, 2025 | finance.yahoo.comCenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15, 2025 | marketbeat.comConcord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15, 2025 | marketbeat.comLeo Wealth LLC Has $748,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co.July 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCOI, AESI, and REGN Company DescriptionsAtlas Energy Solutions NYSE:AESI$13.43 -0.18 (-1.32%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$13.48 +0.05 (+0.41%) As of 07/18/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atlas Energy Solutions Inc. engages in the production, processing, and sale of mesh and sand that are used as a proppant during the well completion process in the Permian Basin of Texas and New Mexico. The company provides transportation and logistics, storage solutions, and contract labor services. It sells its products and services to oil and natural gas exploration and production companies, and oilfield services companies. Atlas Energy Solutions Inc. was founded in 2017 and is headquartered in Austin, Texas.Cogent Communications NASDAQ:CCOI$50.00 -2.91 (-5.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$50.01 +0.01 (+0.02%) As of 07/18/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access, private network, and data center colocation space services in North America, Europe, Oceania, South America, and Africa. The company offers on-net Internet access and private network services to law firms, financial services firms, and advertising and marketing firms, as well as heath care providers, educational institutions and other professional services businesses, other Internet service providers, telephone companies, cable television companies, web hosting companies, media service providers, mobile phone operators, content delivery network companies, and commercial content and application service providers. It also provides Internet access and private network services to customers that are not located in buildings directly connected to its network; and on-net services to customers located in buildings that are physically connected to its network. In addition, the company offers off-net services to corporate customers using other carriers' circuits to provide the last mile portion of the link from the customers' premises to the network. Further, it operates data centers that allow its customers to collocate their equipment and access the network. It serves primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations. Cogent Communications Holdings, Inc. was founded in 1999 and is headquartered in Washington, the District of Columbia.Regeneron Pharmaceuticals NASDAQ:REGN$542.52 -7.48 (-1.36%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$545.00 +2.49 (+0.46%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.